Pacific Biosciences Of California (PACB) EBT Margin (2010 - 2026)

Pacific Biosciences Of California has reported EBT Margin for 17 years, with the latest figure at 114.55% in Q2 2026.

• On a quarterly basis, EBT Margin fell 920.0% year-over-year to 114.55% in Q2 2026; TTM through Jun 2026 was 81.97%, a 25517.0% increase from a year earlier, with the FY2025 full-year figure at 341.28%, down 14030.0% from the prior year.
• EBT Margin was 114.55% for Q2 2026 at Pacific Biosciences Of California, down from 21.76% in the prior quarter.
• The five-year high for EBT Margin was 6.85% in Q4 2024, with the low at 1147.62% in Q1 2025.
• Average EBT Margin over 5 years is 225.15%, with a median of 149.36% recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: EBT Margin slumped 94619 bps in 2025, then jumped 112586 bps in 2026.
• Over 5 years, EBT Margin stood at 308.5% in 2022, then soared by 54 bps to 141.78% in 2023, then soared by 105 bps to 6.85% in 2024, then plunged by 1413 bps to 89.97% in 2025, then fell by 27 bps to 114.55% in 2026.
• The last three EBT Margin figures came in at 114.55% (Q2 2026), 21.76% (Q1 2026), and 89.97% (Q4 2025), per Business Quant data.